Key Takeaways From an Indirect Comparison of ENZA and DARO in mHSPC

Summary for Physicians: ARCHES and ARANOTE Trial Outcomes

Both the ARCHES and ARANOTE trials demonstrated significant clinical benefits when adding novel hormonal therapies to ADT for metastatic hormone-sensitive prostate cancer:

• ARCHES (enzalutamide + ADT): Significant improvement in radiographic progression-free survival
• ARANOTE (apalutamide + ADT): Significant improvement in radiographic progression-free survival

Key findings across both trials:

• Consistent benefits observed across major patient subgroups
• Generally manageable safety profiles

These results support the addition of novel hormonal agents to ADT in the management of metastatic hormone-sensitive prostate cancer.